|
Background
Info
The pharmaceutical industry is
witnessing phenomenal change in the business and regulatory
environment. There has been an increase in the complexity of the
pharmaceutical products.
The Product Lifecycle Management has evolved as an imperative
strategic opportunity for the pharmaceutical companies. PLM
plays a significant role right from the development of a drug to
its long-term establishment on the market.
The pharmaceutical companies are adapting the PLM to improve
their product oriented process and overcome the challenges.
Our 3rd Annual Pharmaceutical PLM conference will address a
range of challenges faced by the pharmaceutical industry and
methods to develop profitable PLM strategies.
-
Gain qualitative insight into the
product lifecycle management solutions
-
Understand the licensing
strategies in the product lifecycle management
-
Discover how to extend the brand
value of your drugs in the market
-
Learn how to successfully manage
regulatory compliance
-
Recognise the challenges in the
current pharmaceutical business model
-
Implement and govern a PLM
strategy
-
Hear the views regarding favoured
PLM strategies from case studies
-
Obtain knowledge on how to
streamline the clinical trial supply management process
-
Gain insight into the global drug
delivery Industry
Who will be there?
VPs, Directors, Heads and Managers of:
Partners, Counsels, Lawyers,
Analysts, Consultants of:
-
Pharmaceuticals
-
Life Sciences
-
Healthcare
Key Speakers :-
-
Dr. Jeremy Everett, Global R&D,
Pfizer
-
Roger Holdsworth, Associate
Director Portfolio Analysis, UCB Group
-
Giovanni Girgenti, Product
Manager, Abbott
-
Mike Rea, Chief Executive Offi cer,
IdeaPharma
-
Sarah Turner, Of Counsel, Lovells
-
Dr. Charles Harding, Partner, D
Young & Co
-
Garreth Duncan, Patent Attorney, D
Young & Co
-
Petra Heyen, Vice President
Regulatory Affairs and PharmacoVigilance, Therabel Pharma
-
Jo Pisani, Partner
–Pharmaceuticals, Price Waterhouse Coopers
-
Markella Kordoyanni, Consultant,
Healthcare, Datamonitor
-
Dr. Will Maier, Director, MAPI-EPI
-
Ashish Menocha, Regional Vice
President, Aurbindo Pharmaceuticals
-
Sheetal Ranganathan, Assistant
Vice President, Evalueserve
Workshop
Pre-Conference Interactive Workshop
Maximising brand assets by excellent Lifecycle Management
planning and execution
Wednesday 28th January 2009
Led by: Dr Tony Ellery, ellery pharma consulting
Former Global Head of Lifecycle Management in Portfolion
Management, Novartis
09:30 - 10:00 Coffee & Registration
10:00 - 16:00 Workshop
Timing includes refreshment breaks
Workshop format
The purpose of the workshop is to allow delegates to engage in
knowledge sharing with their peers in a smaller, less formal
environment than the main conference. As such the audience size
will typically be no more than 20 participants in order to
enable maximum interaction between the workshop leader and
delegates. The format is also more interactive, with less
emphasis on ‘lecture-style’ presentations and more emphasis on
case studies, group discussions, exercises and Q&A sessions.
Key topics to be discussed:
-
The changing environment for
lifecycle management
-
Structures and processes to
optimise lifecycle management
-
Sustainable LCM strategies for the
future
About your Workshop Leader:
Dr Tony Ellery was a practicing veterinarian in the U.K. before
moving to the Swiss pharmaceutical industry in Basel in 1974,
where he has since occupied positions of increasing seniority in
research, development, marketing and sales at different
companies, including Roche, Solco, Ciba Vision and Novartis.
He led R&D in the Novartis Ophthalmics Business Unit for 8
years, during which time his teams succeeded in gaining 3 NCE
approvals each in the US and Europe.
For four years, Tony was the Global Head of Development and then
Project Management for Novartis’ Mature Products Business Unit,
which enjoys sales of over $4 billion per year and is
responsible for the seemingly immortal Voltaren (diclofenac)
brand.
Tony’s last position at Novartis was Global Head of Life Cycle
Management (LCM) in Pharma Portfolio Management, advising
project and brand teams throughout Novartis on brand strategies
and LCM.
In 2005 he led a major project on LCM across Novartis Pharma.
This led to structural and organizational changes which
strengthened the company focus on LCM, also with regard to the
interfaces with Novartis’ generics and OTC businesses.
Tony has served as a member of the Ciba-Geigy Research Advisory
Board and the Novartis Pharma Development Management Board. He
has been a member of the faculty of the European Course for Life
Science Executives of the University of Basel, lecturing on
lifecycle management, and has spoken at many conferences in
Europe and the U.S. on lifecycle, project and portfolio
management.
Tony retired from Novartis in October 2008 to become a
consultant to the pharmaceutical industry, especially in the
areas of lifecycle and project management.
Day 1
09:30 Registration and refreshments
10:00 Opening address from the chair
Mike Rea
CEO
IdeaPharma
10:10 Examining challenges to the current
pharmaceuticalbusiness model
- Lack of new drugs
- Increasing drug development costs
- Aggressive generic competition
- Regulatory controls becoming more
stringent
Mike Rea
CEO
IdeaPharma
10:50 Analysing patent protection strategies
- What can be protected?
- Limitations on protection
- Managing a patent portfolio effectively
- “Offensive” and “Defensive” strategies
Sarah Turner
Of Counsel
Lovells
11:30 Morning refreshments
11:50 Effective brand optimisation
- Development of intangible value
- Increasing the effectiveness of LCM
Strategies
- Increasing the number of lifestyle drugs
has increased the importance of the brand name
- How can brand team extend their drugs
values on the market?
Dr. Alexandra Gruber
Global marketing manager
Baxter Bioscience
12:20 Portfolio management strategy
- Why evaluate projects?
- What methods suit the different stages of
the Product Lifecycle?
- Communication of the outcome
Roger Holdsworth,
Associate Director Portfolio Analysis
UCB Group
13:10 Networking lunch
14:30 Managing regulatory compliance
- Understand major components of RA
strategy during drug development and maintenance
- Understand the embedding of the RA
strategy in the overall development strategy / development
plan
- Understand the multi-disciplinary
approach of the RA strategy
- Understand the basics of RA intelligence
as a basis for RA strategy
Dr. Petra Heyen
Senior Director Regulatory Affairs and Pharmacovigilance
Therabel Pharma
15:10 Examining effectiveness of LCM strategies in pharma
- The latest developments affecting
pharmaceutical ife cycle management strategies
- Extending products life cycle by
optimising their performance after the patent expiry
- Leveraging innovation for success
- Examples of life cycle management
strategies
Giovanni Girgenti
Product Manager
Abbott
15:50 Afternoon refreshments
16:10 Managing the information gaps during the product
lifecycle
- Coherent link between each phase of the
lifecycle
- Identifying critical information
- Analysing technical and scientific
information for the drug delivery process
Markella Kordoyanni
Consultant, Healthcare
Datamonitor
16:50 India -- A strategic offshoring destination for the
pharma marketing/strategy and R&D community
- Leveraging a global resource pool for:
- Marketing analytics
- Patent analytics
- Generating business insights through
Competitive intelligence
- Clinical trials
Sheetal Ranganathan
Assistant Vice President
Evalueserve*
17:30 Closing remarks from the chair
17:40 Networking drinks reception
Take your discussions further and build new relationships in a
relaxed and informal setting.
Day 2
09:30 Registration and refreshments
10:00 Opening address from the chair
Mike Rea
CEO
IdeaPharma
10:10 Case Study:
- Pfizer’s investment in the Research
Centers of Emphasis (RCoEs) and their impact upon
effectiveness and efficiency in Pfizer Global R&D
- What is the mission of Pfizer’s RCoEs?
- How do the RCoEs help Pfizer project
teams to meet their goals and improve productivity?
- What benefits and impacts have we seen
from our RCoE organization
- What are our future aspirations for the
RCoEs?
Dr. Jeremy Everett
Global R&D
Pfizer
10:50 A holistic view of the generic industry sector
- Key generic market trends and
developments
- Pricing and the cost of development
- Impact of generics on pharmaceutical
business model
- Major drivers and resistors to generic
growth
Ashish Menocha
Regional Vice President
Aurbindo Pharmaceuticals
11:30 Morning refreshments
11:50 Product Commercialisation in an era of public risk
aversion
- Changes and challenges to role of
pharmaceutical companies
- regulatory and public
- Conducting product risk analysis -
anticipating problems
- Communication and Collaboration - benefit
vs risk communication
- Allocation of optimal resource
- Monitoring and Managing changes in the
market
Dr.Will Maier
Director, MAPI-EPI Ltd
Former Group Director, Epidemiology, GlaxoSmithKline
12:30 Insight into the global drug delivery industry
- Valuation of IP and patent in drug
delivery
- New protection methods for drug delivery
- Latest techniques for drug delivery
Dr. Mike Webb
Director, Analytical Sciences
Glaxosmithkline*
13:10 Networking lunch
14:30 Analysis of licensing strategies
- Identifying opportunities
- Evaluating drivers and resistors of
licensing
- Managing Alliances
15:10 Clinical Trial Supply Management
- Challenges and best practices in Clinical
Supply Forecasting
- Discussing Complexity in primary and
secondary packaging
- Tracking of drug throughout the value
chain
- Pressures on clinical trials from FDA
regulations
Senior Representative
BearingPoint*
15:50 Afternoon refreshments
16:10 Maximising Patent Term Extensions
- Importance of patent term extensions
- Obtaining patent term extensions
- Strategies for maximising patent term
extensions
Dr Charles Harding
Partner
D Young & Co
Garreth Duncan
Associate
D Young & Co
16:50 Panel Discussion:
- Harmonising product portfolios through
M&A activities
- Acquisition of marketable products
- Companies evolving to become hybrids
- Role of mergers & acquisitions in the
pharmaceutical industry
Jo Pisani
Partner-Pharmaceuticals
PricewaterHousecoopers
17:30 Chair’s closing remarks
17:40 End of Conference
To
download conference brochure, please click
here.. |
Home
|
Contact us
| Login
|
Shopping Cart |
Sign up for a free Newsletter
28th - 30th January 2009,
London
Bharat Book
Bureau